Golubnitschaja, O.O.GolubnitschajaFilep, N.N.FilepYeghiazaryan, K.K.YeghiazaryanBlom, H.J.H.J.BlomHofmann-Apitius, M.M.Hofmann-ApitiusKuhn, W.W.Kuhn2022-03-052022-03-052018https://publica.fraunhofer.de/handle/publica/25597110.1007/s00726-017-2524-0Breast cancer epidemic in the early twenty-first century results in around two million new cases and half-a-million of the disease-related deaths registered annually worldwide. A particularly dramatic situation is attributed to some specific patient subgroups such as the triple-negative breast cancer (TNBC). TNBC is a particularly aggressive type of breast cancer lacking clear diagnostic approach and targeted therapies. Consequently, more than 50% of the TNBC patients die of the metastatic BC within the first 6 months of the diagnosis. In the current study we have hypothesised that multi-omic approach utilising blood samples may lead to discovery of a unique molecular signature of the TNBC subtype. The results achieved demonstrate, indeed, multi-omics as highly promising approach that could be of great clinical utility for development of predictive diagnosis, targeted prevention and treatments tailored to the person-overall advancing the management of the TNBC.en003572005006518journal article